Project Grant R01AR087964
Award Date 9/1/26
Completion Date 8/31/31
Dollars Obligated $421K
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Little Rock, AR 72205, USA
Similar Awards
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded $676,210 to The Washington University on August 5, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The recipient will conduct research into DNMT3A as an epigenetic transcriptional therapeutic target in femoroacetabular impingement (FAI) progression to osteoarthritis. FAI is a pre-arthritic hip condition affecting individuals aged 20 to 40; standard surgical treatment...
- The National Institutes of Health National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded the University of Oregon $343,491 on September 1, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to engineer hemoglobin-based oxygen-carrying spheroids that enhance the viability and secretome activity of injectable mesenchymal stem cells in hypoxic osteoarthritis joint environments. The recipient will develop functional hemoglobin...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded the University of Florida $340,978 on August 11, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to develop microRNA-targeting strategies for tissue-restricted gene delivery in articular joints. The research addresses limitations in intra-articular biologic treatments for joint injury and disease by engineering adeno-associated vectors (AAV) to deliver growth factors such...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded The University of Texas Southwestern Medical Center $613,036 on August 1, 2026, for investigator-initiated research under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The project, "Leveraging Lymphatics to Reverse Heterotopic Ossification," addresses the pathologic formation of extra-skeletal bone occurring in approximately twenty percent of patients following hip...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), part of the National Institutes of Health, awarded $675,318 to Duke University on August 20, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to investigate the relationship between obesity, cartilage mechanics, and osteoarthritis progression and the potential for weight loss and exercise interventions to reverse obesity-associated cartilage degeneration. The research...
- This federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), part of the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $412,610.00 to the Oklahoma Medical Research Foundation (OMRF) to investigate associations between the peripheral blood microbiome and knee osteoarthritis. The key objectives are to determine if baseline peripheral blood bacterial DNA patterns can predict future radiographic and...
- This $298,329 federal Project Grant awarded by the Defense Health Agency on March 1, 2024 under the Military Medical Research and Development program (CFDA 12.420) supports research by the University of Arkansas for Medical Sciences (UAMS) on the role of subchondral bone osteocytes in post-traumatic osteoarthritis. UAMS, a major academic medical center, will leverage its expertise in biomedical research to investigate this specific aspect of osteoarthritis development over the 2-year award...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded $547,767 to the University of Rochester on June 1, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to investigate host mechanisms governing Staphylococcus aureus persistence during implant-associated osteomyelitis. The research uses humanized mouse models and multi-omic analysis of human T cells to understand why some patients resolve acute bone infections while others...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded Ohio University $665,615 on August 15, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to investigate the role of a novel SIRT5 allele in osteoarthritis development. The research examines how altered SIRT5 activity in chondrocytes disrupts cellular metabolism and joint inflammation to increase osteoarthritis susceptibility. The recipient will conduct studies on a rare...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded Syracuse University $467,076 on September 1, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to develop multifunctional microcarriers for immune modulation in osteoarthritis treatment. The project addresses post-traumatic osteoarthritis (PTOA) by investigating site-specific delivery of a macrophage-targeting agent via calcium-zoledronate nanoparticle-loaded microparticles...